Not available
Quote | Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)
Last: | $28.77 |
---|---|
Change Percent: | 0.58% |
Open: | $28.93 |
Close: | $28.77 |
High: | $29.37 |
Low: | $28.56 |
Volume: | 712,784 |
Last Trade Date Time: | 05/20/2024 03:00:00 am |
News | Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)
2024-05-17 15:00:04 ET More on the markets SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards SPY: Get Ready For A Recessionary Bear Market DWS is cautiously optimistic about stocks, but expects 'jittery' market Investors pur...
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and confe...
Message Board Posts | Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)
Subject | By | Source | When |
---|---|---|---|
Just found this one - Well over a | ncstrongman | investorshub | 04/11/2022 12:49:30 PM |
I hope everyone got some 28 es because | ball8281 | investorshub | 12/23/2020 1:24:09 AM |
Wow thats amazing news tomorrow gap up will | ball8281 | investorshub | 12/23/2020 1:23:21 AM |
Boom were heading to 50 dollars a share tomorrow | ball8281 | investorshub | 12/23/2020 1:22:53 AM |
what about the PDUFA on the 8th? will | Diwanssong | investorshub | 11/06/2020 4:54:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing...
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and confe...
Net sales of Qelbree ® increased 75% to $45.1 million compared to first quarter 2023. Total revenues were $143.6 million. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non-GAAP) (1) increased 12% to $100.7 million compared to first ...